Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer

Maximising the potential of AKT inhibitors as anti-cancer treatments

(2017) Jessica S. Brown et al.   PHARMACOLOGY & THERAPEUTICS

Impact of Expression of Vimentin and Axl in Breast Cancer

(2016) Kimihiro Tanaka et al.   Clinical Breast Cancer

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

(2016) Sherri Z. Millis et al.   JAMA Oncology

PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells

(2015) Lei Qi et al.   Cancer Cell International

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

(2015) S. Gupta et al.   CLINICAL CANCER RESEARCH

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis

(2015) Wenting Mi et al.   Oncotarget

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma

(2015) Florian Ewald et al.   Journal of Cancer

Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis

(2015) Xun Yuan et al.   PLoS One

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy

(2015) Carolina Simioni et al.   Oncotarget

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

(2014) Florian Ewald et al.   INVESTIGATIONAL NEW DRUGS

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway

(2014) Dongmei Ji et al.   PLoS One

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma

(2013) Florian Ewald et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

(2013) L M Neri et al.   LEUKEMIA

Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models

(2013) S. Xu et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

(2013) Burhan Hassan et al.   Surgical Oncology Clinics of North America

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

(2012) N. Floc'h et al.   CANCER RESEARCH

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

(2012) T. Sangai et al.   CLINICAL CANCER RESEARCH

Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

(2012) A. M. Petrich et al.   CLINICAL CANCER RESEARCH

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance

(2012) R. Nahta   CURRENT MEDICINAL CHEMISTRY

Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures

(2012) Linglin Chen et al.   EPILEPSIA

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

(2012) Nicole Grabinski et al.   Molecular Cancer

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

(2012) Vijay Ramakrishnan et al.   PLoS One

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

(2011) Kenneth L. Pitter et al.   PLoS One

Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells

(2010) Jie Zheng et al.   CANCER LETTERS

Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation

(2008) X. Wang et al.   CANCER RESEARCH

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

(2008) A. Moreno et al.   ENDOCRINE-RELATED CANCER

Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells

(2008) Dustin C. Hyatt et al.   EXPERIMENTAL CELL RESEARCH